Merck & Co. released data from KEYNOTE-181, a Phase III trial of Keytruda as a monotherapy for the second-line treatment of advanced or metastatic esophageal or esophagogastric junction carcinoma.
Bristol-Myers Squibb Co.’s immuno-oncology treatment Opdivo has now been approved in five tumor types in under two years by the U.S. FDA.
